Recombinant alpha 2-interferon treatment in children with chronic hepatitis B. 1988

F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006521 Hepatitis, Chronic INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. Chronic Hepatitis,Cryptogenic Chronic Hepatitis,Hepatitis, Chronic, Cryptogenic,Hepatitis, Chronic Active,Hepatitis, Chronic Persistent,Chronic Active Hepatitis,Chronic Hepatitis, Cryptogenic,Chronic Persistent Hepatitides,Chronic Persistent Hepatitis,Hepatitis, Cryptogenic Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
April 1988, Lancet (London, England),
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
November 1993, Journal of hepatology,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
January 1986, Journal of hepatology,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
March 2001, Annals of tropical paediatrics,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
August 1998, Yonsei medical journal,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
January 1991, Progress in clinical and biological research,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
January 1990, Digestion,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
March 1991, The American journal of gastroenterology,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
January 1998, The Turkish journal of pediatrics,
F La Banda, and M Ruiz Moreno, and V Carreño, and J Bartolome, and J Gutiez, and S Ramon y Cajal, and A Moreno, and I Mora, and J Carlos Porres
October 1995, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!